Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Software

GRcalculator: an online tool for calculating and mining dose–response data

Authors: Nicholas A. Clark, Marc Hafner, Michal Kouril, Elizabeth H. Williams, Jeremy L. Muhlich, Marcin Pilarczyk, Mario Niepel, Peter K. Sorger, Mario Medvedovic

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Quantifying the response of cell lines to drugs or other perturbagens is the cornerstone of pre-clinical drug development and pharmacogenomics as well as a means to study factors that contribute to sensitivity and resistance. In dividing cells, traditional metrics derived from dose–response curves such as IC 50 , AUC, and E max , are confounded by the number of cell divisions taking place during the assay, which varies widely for biological and experimental reasons. Hafner et al. (Nat Meth 13:521–627, 2016) recently proposed an alternative way to quantify drug response, normalized growth rate (GR) inhibition, that is robust to such confounders. Adoption of the GR method is expected to improve the reproducibility of dose–response assays and the reliability of pharmacogenomic associations (Hafner et al. 500–502, 2017).

Results

We describe here an interactive website (www.​grcalculator.​org) for calculation, analysis, and visualization of dose–response data using the GR approach and for comparison of GR and traditional metrics. Data can be user-supplied or derived from published datasets. The web tools are implemented in the form of three integrated Shiny applications (grcalculator, grbrowser, and grtutorial) deployed through a Shiny server. Intuitive graphical user interfaces (GUIs) allow for interactive analysis and visualization of data. The Shiny applications make use of two R packages (shinyLi and GRmetrics) specifically developed for this purpose. The GRmetrics R package is also available via Bioconductor and can be used for offline data analysis and visualization. Source code for the Shiny applications and associated packages (shinyLi and GRmetrics) can be accessed at www.​github.​com/​uc-bd2k/​grcalculator and www.​github.​com/​datarail/​gr_​metrics.

Conclusions

GRcalculator is a powerful, user-friendly, and free tool to facilitate analysis of dose–response data. It generates publication-ready figures and provides a unified platform for investigators to analyze dose–response data across diverse cell types and perturbagens (including drugs, biological ligands, RNAi, etc.). GRcalculator also provides access to data collected by the NIH LINCS Program (http://​www.​lincsproject.​org/) and other public domain datasets. The GRmetrics Bioconductor package provides computationally trained users with a platform for offline analysis of dose–response data and facilitates inclusion of GR metrics calculations within existing R analysis pipelines. These tools are therefore well suited to users in academia as well as industry.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol. 2013;9(11):708–14.CrossRefPubMedPubMedCentral Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol. 2013;9(11):708–14.CrossRefPubMedPubMedCentral
2.
go back to reference Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Meth. 2016;13(6):521–7.CrossRef Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Meth. 2016;13(6):521–7.CrossRef
3.
go back to reference Hafner M, Niepel M, Sorger PK. Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nat Biotech. 2017;35(6):500–2.CrossRef Hafner M, Niepel M, Sorger PK. Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nat Biotech. 2017;35(6):500–2.CrossRef
4.
go back to reference Niepel M, Hafner M, Chung M, Sorger PK. Measuring cancer drug sensitivity and resistance in cultured cells. In: Current Protocols in Chemical Biology. Edn. Inc.: John Wiley & Sons. p. 2017. Niepel M, Hafner M, Chung M, Sorger PK. Measuring cancer drug sensitivity and resistance in cultured cells. In: Current Protocols in Chemical Biology. Edn. Inc.: John Wiley & Sons. p. 2017.
5.
go back to reference Hafner M, Niepel M, Subramanian K, Sorger PK: Designing drug-response experiments and quantifying their results. In: Current Protocols in Chemical Biology. Edn.: John Wiley & Sons, Inc.; 2017. Hafner M, Niepel M, Subramanian K, Sorger PK: Designing drug-response experiments and quantifying their results. In: Current Protocols in Chemical Biology. Edn.: John Wiley & Sons, Inc.; 2017.
6.
go back to reference RStudio Inc.: shiny: Web Application Framework for R. In.; 2016. RStudio Inc.: shiny: Web Application Framework for R. In.; 2016.
7.
go back to reference R Core Team: R: A language and environment for statistical computing. In. Vienna: R foundation for statistical Computing; 2016. R Core Team: R: A language and environment for statistical computing. In. Vienna: R foundation for statistical Computing; 2016.
8.
go back to reference Niepel M, Hafner M, Duan Q, Wang Z, Paull EO, Chung M, Lu X, Stuart JM, Golub TR, Subramanian A, Ma'ayan A, Sorger PK. Transcriptional landscape of drug response guides the design of specific and potent drug combinations. Nat Commun. In Press. Niepel M, Hafner M, Duan Q, Wang Z, Paull EO, Chung M, Lu X, Stuart JM, Golub TR, Subramanian A, Ma'ayan A, Sorger PK. Transcriptional landscape of drug response guides the design of specific and potent drug combinations. Nat Commun. In Press.
9.
go back to reference Heiser LM, Sadanandam A, Kuo W-L, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci. 2012;109(8):2724–9.CrossRefPubMed Heiser LM, Sadanandam A, Kuo W-L, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci. 2012;109(8):2724–9.CrossRefPubMed
10.
go back to reference Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, et al. Modeling precision treatment of breast cancer. Genome Biol. 2013;14(10):R110.CrossRefPubMedPubMedCentral Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, et al. Modeling precision treatment of breast cancer. Genome Biol. 2013;14(10):R110.CrossRefPubMedPubMedCentral
11.
go back to reference Hafner M, Heiser LM, Niepel M, Wang NJ, Korkola JE, Williams EH, Gray JW, Sorger PK. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci Data. In press. Hafner M, Heiser LM, Niepel M, Wang NJ, Korkola JE, Williams EH, Gray JW, Sorger PK. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci Data. In press.
12.
go back to reference Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature. 2016;533(7603):333–7.CrossRefPubMed Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature. 2016;533(7603):333–7.CrossRefPubMed
13.
go back to reference Hafner M, Niepel M, Sorger PK. Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nat Biotech. 2017;35:500–2.CrossRef Hafner M, Niepel M, Sorger PK. Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nat Biotech. 2017;35:500–2.CrossRef
14.
go back to reference Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109–16.CrossRefPubMed Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109–16.CrossRefPubMed
15.
go back to reference Ritz C, Streibig JC: Bioassay Analysis Using R 2005 2005, 12(5):22. Ritz C, Streibig JC: Bioassay Analysis Using R 2005 2005, 12(5):22.
16.
go back to reference Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.CrossRefPubMedPubMedCentral Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.CrossRefPubMedPubMedCentral
17.
go back to reference Smirnov P, Safikhani Z, El-Hachem N, Wang D, She A, Olsen C, Freeman M, Selby H, Gendoo DMA, Grossmann P, et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics. 2015;32(8):1244–6.CrossRefPubMed Smirnov P, Safikhani Z, El-Hachem N, Wang D, She A, Olsen C, Freeman M, Selby H, Gendoo DMA, Grossmann P, et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics. 2015;32(8):1244–6.CrossRefPubMed
18.
go back to reference Harris LA, Frick PL, Garbett SP, Hardeman KN, Paudel BB, Lopez CF, Quaranta V, Tyson DR. An unbiased metric of antiproliferative drug effect in vitro. Nat Meth. 2016;13(6):497–500.CrossRef Harris LA, Frick PL, Garbett SP, Hardeman KN, Paudel BB, Lopez CF, Quaranta V, Tyson DR. An unbiased metric of antiproliferative drug effect in vitro. Nat Meth. 2016;13(6):497–500.CrossRef
Metadata
Title
GRcalculator: an online tool for calculating and mining dose–response data
Authors
Nicholas A. Clark
Marc Hafner
Michal Kouril
Elizabeth H. Williams
Jeremy L. Muhlich
Marcin Pilarczyk
Mario Niepel
Peter K. Sorger
Mario Medvedovic
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3689-3

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine